Abstract

Purpose: To compare the efficacy of bevacizumab and ranibizumab in the treatment of patients with choroidal neovascularization (CNV).

Methods: Patients who received anti-vascular endothelial growth factor (VEGF) agents for CNV. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were used to compare treatment outcome. BCVA and CMT were by dividing into 3 subgroups; idiopathic CNV, CNV with agerelated macular degeneration (AMD), and polypoidal choroidal vasculopathy (PCV).

Result: In total CNV patients, both anti-VEGFs showed improvement in BCVA and CMT but they did not show difference in changes of BCVA and CMT. In idiopathic CNV, both anti-VEGFs showed improvement in BCVA and CMT but they did not show difference in changes of BCVA and CMT. In AMD, BCVA and CMT were improved only at 3 months after injection and did not show difference in changes of BCVA and CMT. In PCV, BCVA of patients who received bevacizumab improved through the whole study period, otherwise that of patients who received ranibizumab improved only at 3 months later. CMT of patients with PCV had improved until 3 months after injection in both bevacizumab and ranibizumab group.

Conclusion: Intravitreal bevacizumb injection showed similar efficacy and safety as ranibizumab in CNV patients with various pathologic conditions.

Keywords: Choroidal neovascularisation; Bevacizumab; Ranibizumab

Abbreviations: CNV: Choroidal Neovascularization; VEGF: Vascular Endothelial Growth Factor; BCVA: Best-Corrected Visual Acuity; CMT: Central Macular Thickness; AMD: Age-Related Macular Degeneration; PCV: Polypoidal Choroidal Vasculopathy; PDT: Photodynamic Therapy; OCT: Optical Coherence Tomography